Startups channel feed – Endpoints News

Startups channel feed

Boom time: Rubius, Crinetics find big support in upsized IPOs totaling $343M raise

7 years ago

Vivek Ramaswamy strikes again, this time launching a Beijing-based biotech player with a pipeline

7 years ago

The next Nimbus? Head of billion-dollar drug program launches HotSpot with $45M A round

7 years ago

Backers of Tesla and SpaceX fund 29-year-old Alice Zhang's AI-powered neuroscience startup

7 years ago

Thiel-backed Compass adds $49M to A round, bringing total to $132M

7 years ago

Cash-rich Cambridge startup Rubius to build $155M cell therapy manufacturing site in Rhode Island

7 years ago

With tech from Spinraza's maker, French startup Dynacure gets $55M to tackle neuromuscular disease

7 years ago

RIP XTuit: Great brains, hot target and vet CEO Deborah Dunsire in charge couldn’t stop this biotech from going down

7 years ago

CAR macrophage tumor tech created by UPenn star scientists gets $53M

7 years ago

Roivant undergoes major restructuring, cutting and shifting its staff

7 years ago

Food-sourced microbiome drugs get $101M megaround for Flagship's Kaleido

7 years ago

Akero elbows its way into a crowded NASH field, with $65M and a strategy for tackling a blockbuster market

7 years ago

UK startup NodThera banks a $40M round with plans to conquer a closely-studied inflammatory target

7 years ago

J&J opens up a new biotech incubator, polishing the Big Apple's ambitions to create a major hub

7 years ago

With an AstraZeneca cancer drug in one hand, $37M in the other, Shanghai's Alpha Bio zooms into a PhII study

7 years ago

I/O player iTeos lines up a $75M round as it preps for human studies, plans a leap to US hub

7 years ago

Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie

7 years ago

Rich Heyman's Metacrine tacks on another $65M to tackle a superior NASH drug

7 years ago

This startup CEO swiftly gained $260M and a dream team of biotech backers — on both sides of the Pacific

7 years ago

30-year Gilead R&D vet Norbert Bischofberger is starting over as staffer #5 at an upstart biotech — and he’s loving it

7 years ago

Versant backs new approach to gamma delta T cells, co-leads Lava's $18.9M round

7 years ago

Bay Area startup Rain Therapeutics nabs $18M Series A to target lung cancer niche

7 years ago

Forget RNA drugs. Accent gets $40M to develop small molecules that modify RNA instead

7 years ago

Seattle's Nohla closes $45M to bring novel stem cell treatment for leukemia to late-stage trials

7 years ago

First page Previous page 62 63 646566 67 68 Next page Last page